



VACCELERATE CLINICAL TRIAL NETWORK FOR VACCINES



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101037867

VACCELERATE Core Activities

Focus on enabling vaccine trials

- VACCELERATE **Clinical Trials**
- VACCELERATE **Volunteer Registry**
- VACCELERATE **Site Network**
- VACCELERATE **Academy**
- VACCELERATE **Pandemic Preparedness**
- VACCELERATE **Sustainability beyond 2025**

VACCELERATE Clinical Trials

EU-COVAT-1 AGED

Evaluation of Immunogenicity of Third and Fourth mRNA-based Vaccination Dose against COVID-19 in Elderly Persons

- 323 participants across 9 European sites
- LSLV September 2023
- Finalization of CSR planned for end of April 2024
- Part A manuscript published
- Part B manuscript under review with IJID

EU-COVAT-2 BOOSTAVAC

Evaluation of Requirement and Optimal Timing of Booster mRNA Vaccination Dose against COVID-19 in Adults

- 255 participants across 14 European sites
- LSLV expected in May 2024
- Final report expected in August 2024


EU-COVPT-1 CoVacc

Evaluation of Immunogenicity and Reactogenicity of reduced COVID-19 mRNA vaccination regimen in paediatric subjects with prior SARS-CoV-2 immunity

- 31 participants across 5 European sites
- LSLV expected in May 2024
- Primary end-point initial results expected in April 2024


VACCELERATE Volunteer Registry

- Active in 25 countries
- 107,000 volunteers registered
- 22 languages
- >200,000 emails sent out for matching
- Further promotion campaigns



VACCELERATE Site Network

- 491 clinical trial sites registered
- 40 countries in Europe*
- APT-ready framework contracting
- Certification ongoing (next slide)



* includes middle eastern countries



GREEN

BRONZE

SILVER

GOLD

Site Capability questionnaire completed



GCP course certificate and CV of at least PI uploaded in ClinicalSite



Study Nurse Course certificate uploaded (at least one SN/site)



Participation in at least one phase 2 or 3 vaccine trial



VACCELERATE Pandemic Preparedness

→ Firmly position and anchor VACCELERATE in the overall landscape of clinical research preparedness.

- **Plug into the European Pandemic Preparedness Partnership and its precursor BE READY.**
Leads: H. Goossens & Z. D. Pana
- **Intensify the collaboration with the Coordination Mechanism for Cohorts and Trials (CoMeCT).**
Leads: O. A. Cornely & V. C. Simensen
- **Liaise with the yet-to-be-created HERA Sub-Group.**
Leads: O. A. Cornely & H. Goossens
- **Contribute to the ACT-EU initiative.**
Leads: P. Van Damme & I. Leroux-Roels
- **Further develop the concept of preparedness trials for vaccines.**
Leads: O. A. Cornely & Z. D. Pana
- **Organize a table-top drill exercise for pandemic emergencies.**
Leads: H. Goossens & P. Bruijning-Verhagen

VACCELERATE Sustainability Beyond 2025

- The **VACCELERATE Consortium**, an EC-funded project, will be terminated in January 2025.*
- A **new legal entity** with a diversified funding portfolio will ensure long-term sustainability.
- **Business plan** to be drafted by end of 2024.

- Features of the future **VACCELERATE Clinical Trial Network**
 - focus on pandemic preparedness
 - focus on needs of the vaccine trial community
 - transparent and participatory decision-making throughout
 - lean and cost-effective operations
 - participation in academic trials/IITs/industry-sponsored trials.
 - preference for innovative trial methodology such as APT (“adaptive” not just by name!).

* end of funding through EC instruments, status as of May 2024